H. B. Fuller/$FUL
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About H. B. Fuller
H.B. Fuller Co manufactures and sells adhesives, sealants, and other chemical-based products. The company organizes itself into three segments: Hygiene, Health and Consumable Adhesives, Engineering Adhesives, and Construction Adhesives. It generates the maximum revenue from hygiene, health, and consumable adhesives. This segment produces and supplies a full range of specialty industrial adhesives such as thermoplastic, thermoset, reactive, water-based, and solvent-based products for applications in various markets, including packaging, converting, nonwoven, and hygiene (disposable diapers, feminine care, and medical garments) and health and beauty. The company generates around half of its revenue in the United States.
- Ticker
- $FUL
- Sector
- Materials
- Primary listing
- NYSE
- Employees
- 7,100
- Headquarters
- Saint Paul, United States
- Website
- www.hbfuller.com
H. B. Fuller Metrics
BasicAdvanced
$2.7B
13.98
$3.59
0.97
$0.97
1.95%
Price and volume
Market cap
$2.7B
Beta
0.97
52-week high
$68.63
52-week low
$46.70
Average daily volume
894K
Dividend rate
$0.97
Financial strength
Current ratio
1.816
Quick ratio
0.911
Long term debt to equity
1.009
Total debt to equity
1.009
Dividend payout ratio (TTM)
26.22%
Interest coverage (TTM)
3.94%
Profitability
EBITDA (TTM)
610.408
Gross margin (TTM)
32.70%
Net profit margin (TTM)
5.56%
Operating margin (TTM)
12.00%
Effective tax rate (TTM)
26.03%
Revenue per employee (TTM)
$500,000
Management effectiveness
Return on assets (TTM)
5.03%
Return on equity (TTM)
9.58%
Valuation
Price to earnings (TTM)
13.984
Price to revenue (TTM)
0.769
Price to book
1.25
Price to tangible book (TTM)
-9.69
Price to free cash flow (TTM)
27.337
Free cash flow yield (TTM)
3.66%
Free cash flow per share (TTM)
1.836
Dividend yield (TTM)
1.93%
Forward dividend yield
1.95%
Growth
Revenue change (TTM)
1.48%
Earnings per share change (TTM)
73.75%
3-year revenue growth (CAGR)
-0.11%
10-year revenue growth (CAGR)
5.57%
3-year earnings per share growth (CAGR)
10.53%
10-year earnings per share growth (CAGR)
5.26%
3-year dividend per share growth (CAGR)
6.71%
10-year dividend per share growth (CAGR)
5.92%
What the Analysts think about H. B. Fuller
Analyst ratings (Buy, Hold, Sell) for H. B. Fuller stock.
Analyst projections of the future price of H. B. Fuller stock.
Bulls say / Bears say
H.B. Fuller delivered 9% year-on-year adjusted EBITDA growth and lifted its margin to 19.9% in Q3, while pricing and restructuring savings supported higher earnings despite input-cost inflation. This suggests it can protect profitability through a choppy operating environment. (H.B. Fuller)
Project Quantum Leap is on track to deliver about $75 million of annualised savings by 2030, including a further $20 million to $25 million in 2027. If delivered, the factory and supply-chain changes could support higher margins and cash flow. (Stock Analysis)
The planned AMS acquisition would broaden H.B. Fuller’s medical-products exposure, which it expects to grow faster, and add an estimated $55 million of annual run-rate synergies. The deal could strengthen its product mix and add new cross-selling opportunities, although the benefits depend on successful integration. (H.B. Fuller)
Volume fell 3% in Q3, and the company still expects low-single-digit volume declines for fiscal 2026. Revenue growth is therefore relying on price increases rather than stronger underlying demand. (H.B. Fuller)
The AMS purchase is to be debt-funded, and Fitch estimated pro forma leverage of about 4.7 times EBITDA, above its 4.5-times negative rating sensitivity. Combining the acquisition with the large Quantum Leap restructuring also leaves the company with substantial integration and delivery work. (Fitch Ratings)
Petrochemical supply chains remain disrupted and raw-material prices are elevated, while H.B. Fuller has increased inventory to protect customer supply. Further cost shocks or delays in passing them on could squeeze margins and tie up cash. (H.B. Fuller)
Data summarised monthly by Lightyear AI. Last updated on 2 Nov 2026.
H. B. Fuller Financial Performance
Revenues and expenses
H. B. Fuller Earnings Performance
Company profitability
Upcoming events
No upcoming events
H. B. Fuller News
AllArticlesVideos
H.B. Fuller Rejects Ancora's Latest Acquisition Bid, Plans to Consider Selling Noncore Businesses
WSJ2 weeks ago
H.B. Fuller Announces Pricing of $850 Million Debt Offering
Business Wire4 weeks ago
Ancora Highlights the Cost of H.B. Fuller's Failure to Engage, Contrasting It with Constructive Engagement at Ashland
Business Wire1 month ago
Funds containing H. B. Fuller
AllUSDEURGBP
Fund name | Fund size | $FUL weighting |
|---|---|---|
iShares S&P SmallCap 600$IDP6 | $3.2B | 0.16% |
iShares S&P Small Cap 600£ISP6 | $3.2B | 0.16% |
SPDR S&P US Dividend Aristocrats€SPYD | $3.8B | 0.11% |
SPDR S&P US Dividend Aristocrats£USDV | $3.8B | 0.11% |
SPDR Russell 2000 US Small Cap€R2US | $5.3B | 0.10% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.